Accera, Inc. Awarded "Company of the Year" by the Colorado BioScience Association
November 11, 2009
Broomfield, CO, November 11, 2009 – Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced today it has been elected as The Colorado Bioscience Association's 2009 "Company of the Year" Award recipient.
John Collar, President & CEO of the Colorado BioScience Association, said, "Accera is the first and only private biotech company in the US to have researched, developed and launched a prescription CNS product and to have done it in record time – eight years from inception to launch."
Mr. Collar continued, "The CBSA facilitates the growth of the bioscience industry in Colorado through advocacy, representation and service. CBSA also supports the economic development of Colorado through the creation of a premier bioscience cluster within the state."
Steve Orndorff, Ph.D., founder, president and CEO of Accera, stated, "It is an honor for Accera and our employees, who have worked diligently on discovery and development of Axona™, our lead therapeutic for mild-to-moderate Alzheimer's disease, to be honored with this award. Our team is pleased to be recognized as a valued member of Colorado's bioscience industry. We remain committed to Colorado and to developing therapeutics for central nervous system diseases."
"This award is especially timely given that November is National Alzheimer's Disease Awareness Month," concluded Dr. Orndorff. Alzheimer's disease affects 5.3 million people and their families each year.
The award was presented during the Annual Awards Dinner on November 10 at the Grand-Hyatt Denver's Imperial Ballroom in Denver, CO.
Accepting the award on behalf of Accera, Inc. were Dr. Sam Henderson, scientific founder and Executive Director of R&D, and Eric Schauble, Senior Director of Corporate Development.
Axona is a first-in-class prescription medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Axona targets neuronal hypometabolism, a metabolic deficiency and imbalance associated with Alzheimer's disease, by providing ketone bodies as an alternative energy source for brain cells that have defective energy metabolism and can no longer utilize glucose. Axona has been shown to safely improve cognitive function and memory in AD patients and in pre-clinical animal models of dementia. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies. Axona is a medical food as defined by the Orphan Drug Act and is regulated by the Food and Drug Administration. For more information about Axona, please visit www.about-axona.com or ask your physician.